Catalyst Event
Hanmi Pharm Co Ltd (128940) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/16/2026, 12:00:00 AM
Announced a partnership with Zetema on March 16, 2026, to enter the U.S. skin booster market with 'Hialuma' distribution; expected to have a >1% price impact from global market expansion scheduled.
Korean Translation
제테마와의 파트너십을 통한 미국 시장 진출 계획을 2026년 3월 16일 발표함. '히알루마'의 미국 유통이 예정되어 있으며 1% 이상의 주가 상승이 예정됨.
Related Recent Events
D&D Pharmatech Inc (347850) · Other
Top-line results from the Phase 2 clinical trial of MASH treatment candidate DD01, including 48-week liver biopsy data, are scheduled to be announced around May 2026. High importance is estimated due to the potential for significant price impact (≥10%) upon the release of Phase 2 clinical trial results scheduled
5/31/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
The 14th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Yuhan Corp (000100) · Other
The 103rd Annual General Meeting to approve FY2025 financial statements and a cash dividend of KRW 600 per common share on March 20, 2026, with minimal market impact anticipated, is scheduled.
3/20/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA-targeting ADC candidates at the AACR Annual Meeting scheduled. Expected impact is Medium as major conference presentations typically influence biotech valuations.
3/18/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
In its 2025 annual report filed on March 18, 2026, the company removed its '1 Product, 1 Trillion KRW Sales' slogan, shifting its strategic focus to fostering multiple global blockbuster drugs; low market impact from strategic shift is expected.
3/18/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Announced a shareholder return plan on March 16, 2026, to be proposed at the March 31 AGM, including the cancellation of 85,316 treasury shares and a record-high cash dividend; expected to cause a >10% price impact due to significant shareholder value enhancement expected.
3/16/2026, 12:00:00 AM